welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Researchers Overcome Hurdle in CRISPR Gene Editing for Muscular Dystrophy
The gene editing technique known as CRISPR is a revolutionary approach to treating inherited diseases. However, the tool has yet to be used to effectively treat long-term, chronic conditions. A research team led by Dongsheng Duan, PhD, at the University of Missouri School of Medicine has identified and overcome a barrier in CRISPR gene editing that may lay the foundation for sustained treatments using the technique.
CRISPR gene editing is inspired by the body’s natural defensive ability to fend off viruses. The technology enables researchers to alter DNA sequences by cutting out and replacing a mutation in the genome, which has the potential to treat a variety of genetic diseases and conditions. Duan, along with his collaborators at MU, the National Center for Advancing Translational Sciences at the National Institutes of Health and Duke University, are studying how to harness CRISPR to treat Duchenne muscular dystrophy (DMD).
rareRelated
-
CRISPR/Cas9-Generated Mouse Model of Duchenne Muscular Dystrophy Recapitulating a Newly Identified Large 430 Kb Dele...Exon skipping is a promising strategy fo...
-
Systemic Gene Delivery Clinical Trial for Duchenne Muscular DystrophyThe proposed clinical trial is a single-...
-
Shape Therapeutics’s RNA Editing Gene Therapy Platform Focused on Curing Genetic DiseasesShape Therapeutics, Inc. (ShapeTx), a de...
-
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Progra...Sarepta Therapeutics, Inc., a commercial...
-
Champions to CureDuchenne Gala 2018https://www.youtube.com/watch?v=cmXFoPKU...
-
AAV-Based Gene Therapies for the Muscular DystrophiesMuscular dystrophy is a group of progres...
-
Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystr...Sarepta Therapeutics, Inc., a commercial...
